These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 32452122)

  • 1. A newborn with a large NTRK fusion positive infantile fibrosarcoma successfully treated with larotrectinib.
    Caldwell KJ; De La Cuesta E; Morin C; Pappo A; Helmig S
    Pediatr Blood Cancer; 2020 Sep; 67(9):e28330. PubMed ID: 32452122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NTRK-fused central nervous system tumours: clinicopathological and genetic insights and response to TRK inhibitors.
    Kim EE; Park CK; Kim SK; Phi JH; Paek SH; Choi JY; Kang HJ; Lee JH; Won JK; Yun H; Park SH
    Acta Neuropathol Commun; 2024 Jul; 12(1):118. PubMed ID: 39014476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical characteristics and treatment patterns of patients with
    Willis C; Au T; Hejazi A; Griswold C; Schabath MB; Thompson J; Malhotra J; Federman N; Ko G; Appukkuttan S; Warnock N; Kong SX; Hocum B; Brixner D; Stenehjem D
    J Manag Care Spec Pharm; 2024 Jul; 30(7):672-683. PubMed ID: 38950155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving outcomes in pediatric NTRK gene fusion-positive solid tumors: importance of genomic testing and targeted therapy with the TRK inhibitor larotrectinib.
    Laetsch TW
    Clin Adv Hematol Oncol; 2024 May; 22 Suppl 3(4):1-11. PubMed ID: 38739704
    [No Abstract]   [Full Text] [Related]  

  • 5. Beyond Clinical Trials: Understanding Neurotrophic Tropomyosin Receptor Kinase Inhibitor Challenges and Efficacy in Real-World Pediatric Oncology.
    Vince CSC; Brassesco MS; Mançano BM; Gregianin LJ; Carbone EK; do Amaral E Castro A; Dwan VSY; Menezes da Silva RZ; Mariano CS; da Mata JF; Silva MO; Caran EMM; Macedo CD; Alves da Costa G; Esteves TC; Silva LN; Ferman SE; Martins FD; Cristófani LM; Odone-Filho V; Silva MM; Reis RM; Pianovski MAD; Campregher PV; Kunii MS; de Sá Rodrigues KE; Carvalho Filho NP; Valera ET;
    JCO Precis Oncol; 2024 May; 8():e2300713. PubMed ID: 38810175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic benefit of larotrectinib over the historical standard of care in patients with locally advanced or metastatic infantile fibrosarcoma (EPI VITRAKVI study).
    Orbach D; Carton M; Khadir SK; Feuilly M; Kurtinecz M; Phil D; Vokuhl C; Koscielniak E; Pierron G; Lemelle L; Sparber-Sauer M
    ESMO Open; 2024 May; 9(5):103006. PubMed ID: 38657345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of NTRK inhibitors in patients with NTRK fusion-positive lung and thyroid cancers.
    Hong DS; Drilon A; Wirth LJ
    Clin Adv Hematol Oncol; 2024; 22 Suppl 5(6):1-20. PubMed ID: 38953725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Larotrectinib versus historical standard of care in patients with infantile fibrosarcoma: protocol of EPI-VITRAKVI.
    Carton M; Del Castillo JP; Colin JB; Kurtinecz M; Feuilly M; Pierron G; Arvis P; Khadir SK; Sparber-Sauer M; Orbach D
    Future Oncol; 2023 Aug; 19(24):1645-1653. PubMed ID: 37133249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of radioiodine (RAI)-avidity restoration for NTRK fusion-positive RAI-resistant metastatic thyroid cancers.
    Syed AR; Gorana A; Nohr E; Yuan XK; Amin MASc P; Ghaznavi S; Lamb D; McIntyre J; Eszlinger M; Paschke R
    Eur Thyroid J; 2024 Jun; 13(3):. PubMed ID: 38642578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive clinicopathological, molecular, and methylation analysis of mesenchymal tumors with NTRK and other kinase gene aberrations.
    Klubíčková N; Dermawan JK; Mosaieby E; Martínek P; Vaněček T; Hájková V; Ptáková N; Grossmann P; Šteiner P; Švajdler M; Kinkor Z; Michalová K; Szepe P; Plank L; Hederová S; Kolenová A; Spasov NJ; Kosemehmetoglu K; Pažanin L; Špůrková Z; Baník M; Baumruk L; Meyer A; Kalmykova A; Koshyk O; Michal M; Michal M
    J Pathol; 2024 May; 263(1):61-73. PubMed ID: 38332737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibroblastic orbital tumour with NTRK1 fusion transcript: when TRK inhibitors rescue surgery.
    Nahon-Estève S; Orbach D; Le Loarer F; Hofman P; Lassalle S
    Can J Ophthalmol; 2024 Aug; 59(4):e407-e409. PubMed ID: 38096907
    [No Abstract]   [Full Text] [Related]  

  • 12. Induction of resistance to neurotrophic tropomyosin-receptor kinase inhibitors by HMGCS2 via a mevalonate pathway.
    Kato Y; Matsumoto M; Takano N; Hirao M; Matsuda K; Tozuka T; Onda N; Nakamichi S; Takeuchi S; Miyanaga A; Noro R; Gemma A; Seike M
    Cancer Med; 2024 Jun; 13(12):e7393. PubMed ID: 38923428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival Outcomes of Patients With Tropomyosin Receptor Kinase Fusion-Positive Cancer Receiving Larotrectinib Versus Standard of Care: A Matching-Adjusted Indirect Comparison Using Real-World Data.
    Bokemeyer C; Paracha N; Lassen U; Italiano A; Sullivan SD; Marian M; Brega N; Garcia-Foncillas J
    JCO Precis Oncol; 2023 Jan; 7():e2200436. PubMed ID: 36689698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the NTRK Fusion Gene in Pancreatic Acinar Cell Carcinoma: A Case Report and Review of the Literature.
    Gupta M; Sherrow C; Krone ME; Blais EM; Pishvaian MJ; Petricoin EF; Matrisian LM; DeArbeloa P; Gregory G; Brown A; Zalewski O; Prinzing G; Roche C; Kanehira K; Mukherjee S; Iyer R; Fountzilas C
    J Natl Compr Canc Netw; 2021 Jan; 19(1):10-15. PubMed ID: 33406492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to Repotrectinib After Development of
    Chen MF; Yang SR; Shia J; Girshman J; Punn S; Wilhelm C; Kris MG; Cocco E; Drilon A; Raj N
    JCO Precis Oncol; 2023 May; 7():e2200697. PubMed ID: 37262390
    [No Abstract]   [Full Text] [Related]  

  • 16. Management of patients with NTRK fusion-positive thyroid cancer.
    Wirth LJ
    Clin Adv Hematol Oncol; 2024; 22 Suppl 5(6):9-15. PubMed ID: 38953728
    [No Abstract]   [Full Text] [Related]  

  • 17. Management of patients with NTRK fusion-positive lung cancer.
    Drilon A
    Clin Adv Hematol Oncol; 2024; 22 Suppl 5(6):5-9. PubMed ID: 38953727
    [No Abstract]   [Full Text] [Related]  

  • 18. Imaging characterization of paediatric tumours with the neurotrophic tyrosine receptor kinase fusion transcript.
    Hermann AL; Lemelle L; Pierron G; Gauthier A; Nicolas N; Cardoen L; Moalla S; Petit P; Morel B; Ducou Le Pointe H; Hassani A; Fréneaux P; Guillemot D; Carton M; Corradini N; Rome A; Castex MP; Defachelles AS; Schleiermacher G; Berlanga P; Delattre O; Orbach D; Brisse HJ
    Br J Radiol; 2024 Mar; 97(1156):734-743. PubMed ID: 38327010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Healthcare decision-making for tumour-agnostic therapies in Europe: lessons learned.
    Hogervorst MA; van Hattem CC; Sonke GS; Mantel-Teeuwisse AK; Goettsch WG; Bloem LT
    Drug Discov Today; 2024 Jul; 29(7):104031. PubMed ID: 38796096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Larotrectinib in a NTRK-rearranged soft tissue sarcoma in the neoadjuvant setting: A case report.
    Percy C; Schubert T; Galant C; Kirchgesner T; Mazzeo F
    Clin Case Rep; 2021 Mar; 9(3):1694-1698. PubMed ID: 33768917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.